Axon Biochemicals BV
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Axon Biochemicals BV
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
NellOne Therapeutics Inc. believes it can help patients restore muscle mass and function thanks to a gene called Nell-1. If early studies bear out, the company’s research could yield protein therapeutics capable of regenerating muscle around joint replacements and even in hearts damaged by heart attacks. An in vitro study of heart muscle cells showed the protein could protect those cells and prevent them from dying in the very kind of low-oxygen situation that typifi es the conditions that heart muscle cells encounter during a heart attack. NellOne has chosen to develop its technology as a wound-healing therapy initially, because that research is farthest along and the path to market is shorter than for a cardiovascular indication.
Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.
Robotic surgery systems represent one of the fastest growing segments of the overall endoscopic surgery products market. These technologies allow surgeons to perform complex microsurgical tasks with greater precision and smaller incisions, thereby improving cosmesis, reducing postoperative pain, and shortening the length of hospital stay.
- Contract Research, Toxicology Testing-CRO